ProPhase Labs, Inc. Nebula Genomics secures major international B2B deal – Additional significant B2B deals in final stages Ahead of schedule, Pharmaloz Manufacturing accelerates capacity ...

Ted Karkus, CEO of ProPhase Labs, will present to shareholders today, May 20, 2025, at 10:00 a.m. EST during the live Virtual Non-Deal Roadshow Series. The details are available below. In January ...

ProPhase Labs, Inc. (NASDAQ:PRPH) Q4 2024 Earnings Call Transcript March 31, 2025 ProPhase Labs, Inc. misses on earnings expectations. Reported EPS is $-1.86 EPS, expectations were $-0.24.

ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products.

PROPHASE LABS ($PRPH) posted quarterly earnings results on Tuesday, May 20th. The company reported earnings of -$0.12 per share, beating estimates of -$0.18 by $0.06 ...

ProPhase Labs (NASDAQ:PRPH) stock rose +12% Tuesday premarket as it named Stu Hollenshead as Chief Operating Officer, marking a pivotal step in the company’s expansion into consumer-centered ...

Diagnostics and genomics company ProPhase Labs is building a genomics lab as part of an effort to expand its in-house clinical and genomics testing capabilities. The company said June 13 that it ...

Few companies are eager for a bankruptcy filing, but ProPhase Labs might be an exception. To collect accounts receivables from its days processing Covid-19 tests done inside pop-up tents in New ...

Navidea Biopharmaceuticals Inc. NAVB announced Friday that it had rejected an unsolicited ProPhase Labs Inc. PRPH offer for certain Navidea assets, saying the proposal undervalues Navidea and is ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...